TY - JOUR
T1 - Synthesis of Injectable Shear-Thinning Biomaterials of Various Compositions of Gelatin and Synthetic Silicate Nanoplatelet
AU - Xue, Chengbin
AU - Xie, Huifang
AU - Eichenbaum, James
AU - Chen, Yi
AU - Wang, Yonggang
AU - van den Dolder, Floor W.
AU - Lee, Junmin
AU - Lee, Kang Ju
AU - Zhang, Shiming
AU - Sun, Wujin
AU - Sheikhi, Amir
AU - Ahadian, Samad
AU - Ashammakhi, Nureddin
AU - Dokmeci, Mehmet R.
AU - Kim, Han Jun
AU - Khademhosseini, Ali
N1 - Publisher Copyright:
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Injectable shear-thinning biomaterials (iSTBs) have great potential for in situ tissue regeneration through minimally invasive therapeutics. Previously, an iSTB was developed by combining gelatin with synthetic silicate nanoplatelets (SNPs) for potential application to hemostasis and endovascular embolization. Hence, iSTBs are synthesized by varying compositions of gelatin and SNPs to navigate their material, mechanical, rheological, and bioactive properties. All compositions (each component percentage; 1.5–4.5%/total solid ranges; 3–9%) tested are injectable through both 5 Fr general catheter and 2.4 Fr microcatheter by manual pressure. In the results, an increase in gelatin contents causes decrease in swellability, increase in freeze-dried hydrogel scaffold porosity, increase in degradability and injection force during iSTB fabrication. Meanwhile, the amount of SNPs in composite hydrogels is mainly required to decrease degradability and increase shear thinning properties of iSTB. Finally, in vitro and in vivo biocompatibility tests show that the 1.5–4.5% range gelatin–SNP iSTBs are not toxic to the cells and animals. All results demonstrate that the iSTB can be modulated with specific properties for unmet clinical needs. Understanding of mechanical and biological consequences of the changing gelatin–SNP ratios through this study will shed light on the biomedical applications of iSTB on specific diseases.
AB - Injectable shear-thinning biomaterials (iSTBs) have great potential for in situ tissue regeneration through minimally invasive therapeutics. Previously, an iSTB was developed by combining gelatin with synthetic silicate nanoplatelets (SNPs) for potential application to hemostasis and endovascular embolization. Hence, iSTBs are synthesized by varying compositions of gelatin and SNPs to navigate their material, mechanical, rheological, and bioactive properties. All compositions (each component percentage; 1.5–4.5%/total solid ranges; 3–9%) tested are injectable through both 5 Fr general catheter and 2.4 Fr microcatheter by manual pressure. In the results, an increase in gelatin contents causes decrease in swellability, increase in freeze-dried hydrogel scaffold porosity, increase in degradability and injection force during iSTB fabrication. Meanwhile, the amount of SNPs in composite hydrogels is mainly required to decrease degradability and increase shear thinning properties of iSTB. Finally, in vitro and in vivo biocompatibility tests show that the 1.5–4.5% range gelatin–SNP iSTBs are not toxic to the cells and animals. All results demonstrate that the iSTB can be modulated with specific properties for unmet clinical needs. Understanding of mechanical and biological consequences of the changing gelatin–SNP ratios through this study will shed light on the biomedical applications of iSTB on specific diseases.
UR - http://www.scopus.com/inward/record.url?scp=85081737216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081737216&partnerID=8YFLogxK
U2 - 10.1002/biot.201900456
DO - 10.1002/biot.201900456
M3 - Article
C2 - 32107862
AN - SCOPUS:85081737216
SN - 1860-6768
VL - 15
JO - Biotechnology Journal
JF - Biotechnology Journal
IS - 8
M1 - 1900456
ER -